Dyslipidaemia and global cardiovascular risk: Clinical issues

European Heart Journal, Supplement

Volumn 8, Issue F, 2006, Pages

  Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cardiovascular risk; Cardiovascular risk engines; Coronary heart disease; Dyslipidaemia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ARTIFICIAL NEURAL NETWORK; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DATA ANALYSIS; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FOLLOW UP; GENOTYPE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; METABOLIC SYNDROME X; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVIEW; RISK FACTOR; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SMOKING; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33749033623     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sul040     Document Type: Review

References (47)

1. European Heart Network, British Heart Foundation. European cardiovascular disease statistics. 2005 edition. www.ehnheart.org (December 2005).
2. Unal B, Critchley JA, Capewell S. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. BMJ 2005;331:614.
3. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
4. World Health Organization, Regional Office for Europe. Mortality by 67 causes of death, age and sex (HFA-MDB). www.data.euro.who. int/hfamdb/ (December 2005).
5. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190-1201.
6. Kouvaras G, Bacoulas G. Unstable angina pectoris as a warning symptom before acute myocardial infarction. Q J Med 1987;64:679-684.
7. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
8. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997;20:704-708.
9. Lowel H, Koenig W, Engel S, Hormann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 2000;43:218-226.
10. Sala J, Masia R, Gonzalez de Molina FJ, Fernandez-Real JM, Gil M, Bosch D, Ricart W, Senti M, Marrugat J. Short-term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission. J Epidemiol Commun Health 2002;56:707-712.
11. Hadjadj S, Coisne D, Mauco G, Ragot S, Duengler F, Sosner P, Torremocha F, Herpin D, Marechaud R. Prognostic value of admission plasma glucose and HbA in acute myocardial infarction. Diabet Med 2004;21:305-310.
12. Dawber TR, Meadors GF, Moore FEJ. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951;41:279-286.
13. Empana JP, Ducimetiere P, Arveiler D, Ferrieres J, Evans A, Ruidavets JB, Haas B, Yarnell J, Bingham A, Amouyel P, Dallongeville J. Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME study. Eur Heart J 2003;24:1903-1911.
14. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937-945.
15. Assmann G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. In: Assmann G, ed. Lipid Metabolism Disorders and Coronary Heart Disease. München: MMV Medizin Verlag; 1993. p19-68.
16. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-315.
17. Online PROCAM risk calculator. www.chdrisk.uni-muenster.de/calculator.php (December 2005).
18. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
19. May M. Commentary: improved coronary risk prediction using neural networks. Int J Epidemiol 2002;31:1262-1264.
20. Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002;31:1253-1262.
21. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2003;10:S1-S10.
22. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992;70:733-737.
23. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(suppl.):S11-S20.
24. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med 1977;62:707-714.
25. Marcovina SM, Koschinsky ML. A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment? Semin Vasc Med 2002;2:335-344.
26. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, a prospective case-control study in a general population sample of middle aged men. BMJ 1990;301:1248-1251.
27. Stubbs P, Seed M, Lane D, Collinson P, Kendall F, Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998;19:1355-1364.
28. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein(a) an independent risk factor for ischaemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-525.
29. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch HG, Schuierer G, von Eckardstein A. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischaemic stroke in childhood. Blood 1999;94:3678-3682.
30. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-2199.
31. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
32. ton Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434-439.
33. Incalcaterra E, Hoffmann E, Averna MR, Caimi G. Genetic risk factors in myocardial infarction at young age. Minerva Cardioangiol 2004;52:287-312.
34. Auer J, Weber T, Berent R, Lassnig E, Lamm G, Eber B. Genetic polymorphisms in cytokine and adhesion molecule genes in coronary artery disease. Am J Pharmacogenomics 2003;3:317-328.
35. Green F, Humphries S. Genetic determinants of arterial thrombosis. Baillieres Clin Haematol 1994;7:675-692.
36. Kajimoto K, Shioji K, Ishida C, Iwanaga Y, Kokubo Y, Tomoike H, Miyazaki S, Nonogi H, Goto Y, Iwai N. Validation of the association between the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a Japanese population. Circ J 2005;69:1029-1034.
37. Morrison AC, Bray MS, Folsom AR, Boerwinkle E. ADD1 460 W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 2002;39:1053-1057.
38. Mielke CH, Shields JP, Broemeling LD. Coronary artery calcium, coronary artery disease, and diabetes. Diabetes Res Clin Pract 2001;53:55-61.
39. Schmermund A, Mohlenkamp S, Erbel R. Coronary artery calcium and its relationship to coronary artery disease. Cardiol Clin 2003;21:521-534.
40. Hosoi M, Sato T, Yamagami K, Hasegawa T, Yamakita T, Miyamoto M, Yoshioka K, Yamamoto T, Ishii T, Tanaka S, Itoh A, Haze K, Fujii S. Impact of diabetes on coronary stenosis and coronary artery calcification detected by electron-beam computed tomography in symptomatic patients. Diabetes Care 2002;25:696-701.
41. Grundy SM. Coronary plaque as a replacement for age as a risk factor in global risk assessment. Am J Cardiol 2001;88:8E-11E.
42. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2897.
43. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
44. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
45. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S, ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-913.
46. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517.
47. Taylor AJ, Sullenberger LE, Lee HJ. ARBITER 3: atherosclerosis regression during open-label continuation of extended-release niacin following ARBITER 2. (Abstract 943). Circulation 2005;112.